DE3773953D1 - Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen. - Google Patents
Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen.Info
- Publication number
- DE3773953D1 DE3773953D1 DE8787102198T DE3773953T DE3773953D1 DE 3773953 D1 DE3773953 D1 DE 3773953D1 DE 8787102198 T DE8787102198 T DE 8787102198T DE 3773953 T DE3773953 T DE 3773953T DE 3773953 D1 DE3773953 D1 DE 3773953D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- skin
- viral
- factor
- treating viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 3
- 208000028990 Skin injury Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 208000031709 Skin Manifestations Diseases 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 208000017520 skin disease Diseases 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000006037 cell lysis Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60D—VEHICLE CONNECTIONS
- B60D1/00—Traction couplings; Hitches; Draw-gear; Towing devices
- B60D1/58—Auxiliary devices
- B60D1/66—Props
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transportation (AREA)
- Mechanical Engineering (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/830,662 US4822605A (en) | 1986-02-18 | 1986-02-18 | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3773953D1 true DE3773953D1 (de) | 1991-11-28 |
Family
ID=25257431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8787102198T Expired - Lifetime DE3773953D1 (de) | 1986-02-18 | 1987-02-17 | Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen. |
Country Status (10)
Country | Link |
---|---|
US (1) | US4822605A (de) |
EP (1) | EP0233629B1 (de) |
JP (1) | JPS62240627A (de) |
AT (1) | ATE68702T1 (de) |
AU (1) | AU598232B2 (de) |
CA (1) | CA1297006C (de) |
DE (1) | DE3773953D1 (de) |
DK (1) | DK82287A (de) |
IL (1) | IL82351A (de) |
ZA (1) | ZA87702B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ219027A (en) * | 1986-01-24 | 1989-09-27 | Genentech Inc | Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin |
US4879111A (en) * | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
PH26198A (en) * | 1986-05-27 | 1992-03-18 | Schering Corp | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
CA1292686C (en) * | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
US5266310A (en) * | 1987-09-17 | 1993-11-30 | Boehringer Ingelheim International Gmbh | Stabilization of therapeutically active proteins in pharmaceutical preparations |
DE3731255A1 (de) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen |
US7307166B1 (en) | 1987-10-28 | 2007-12-11 | Wellstat Therapeutics Corporation | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis |
US6241982B1 (en) * | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
US5342613A (en) * | 1988-12-27 | 1994-08-30 | Health Research Inc. | Pharmaceutical compositions and use thereof in the treatment of psoriasis |
DE59000270D1 (de) * | 1989-04-11 | 1992-10-01 | Boehringer Ingelheim Int | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. |
US5028421A (en) * | 1989-05-25 | 1991-07-02 | Embrex, Inc. | Method of treating birds |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
US5795964A (en) * | 1990-06-27 | 1998-08-18 | Biogen, Inc. | Lymphotoxin-beta and lymphotoxin-beta complexes |
ES2157889T3 (es) * | 1990-06-27 | 2001-09-01 | Biogen Inc | Linfotoxina complejada de superficie. |
US7030080B2 (en) * | 1990-06-27 | 2006-04-18 | Biogen, Inc. | Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof |
US5082472A (en) * | 1990-11-05 | 1992-01-21 | Mallouk Robert S | Composite membrane for facilitated transport processes |
JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度tcf製剤 |
US5547661A (en) * | 1994-02-22 | 1996-08-20 | Helene Curtis, Inc. | Antiperspirant deodorant compositions |
IL112649A (en) * | 1994-02-22 | 1999-12-22 | Curtis Helene Ind Inc | Topically effective compositions for application to the skin or hair |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5599614A (en) * | 1995-03-15 | 1997-02-04 | W. L. Gore & Associates, Inc. | Integral composite membrane |
USRE37701E1 (en) * | 1994-11-14 | 2002-05-14 | W. L. Gore & Associates, Inc. | Integral composite membrane |
US5547551A (en) * | 1995-03-15 | 1996-08-20 | W. L. Gore & Associates, Inc. | Ultra-thin integral composite membrane |
USRE37307E1 (en) | 1994-11-14 | 2001-08-07 | W. L. Gore & Associates, Inc. | Ultra-thin integral composite membrane |
US6254978B1 (en) | 1994-11-14 | 2001-07-03 | W. L. Gore & Associates, Inc. | Ultra-thin integral composite membrane |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
PL186018B1 (pl) * | 1995-11-30 | 2003-09-30 | Regents Board Of | Sposoby i kompozycje do diagnozowania i leczenia nowotworu |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び/又は治療剤 |
CA2253629A1 (en) * | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent for preventing and/or treating cachexia |
US6130175A (en) * | 1997-04-29 | 2000-10-10 | Gore Enterprise Holdings, Inc. | Integral multi-layered ion-exchange composite membranes |
US6638659B1 (en) | 1999-04-30 | 2003-10-28 | University Of Connecticut | Membrane electrode assemblies using ionic composite membranes |
US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
US6211243B1 (en) | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
US6410597B1 (en) * | 2000-02-25 | 2002-06-25 | Virginia Commonwealth University | Hydroxyalkyl amide analogs of ceramide |
US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US6613203B1 (en) | 2001-09-10 | 2003-09-02 | Gore Enterprise Holdings | Ion conducting membrane having high hardness and dimensional stability |
US6668753B2 (en) | 2002-02-13 | 2003-12-30 | Embrex, Inc. | Methods and apparatus for delivering fluid to egg injection devices |
US6860225B2 (en) * | 2002-05-06 | 2005-03-01 | Embrex, Inc. | Methods and apparatus for identifying live eggs by detecting embryo heart rate and/or motion |
US7373561B2 (en) * | 2002-10-29 | 2008-05-13 | Broadcom Corporation | Integrated packet bit error rate tester for 10G SERDES |
WO2004050683A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
US20090232748A1 (en) * | 2003-11-07 | 2009-09-17 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
US20050100601A1 (en) * | 2003-11-07 | 2005-05-12 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
US20050244402A1 (en) * | 2004-04-30 | 2005-11-03 | Villanueva Julie M | Absorption of pain-causing agents |
EP2046121B1 (de) | 2006-07-14 | 2012-08-22 | Stiefel Research Australia Pty Ltd | Pharmazeutischer schaum mit fettsäure |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
US8067375B2 (en) * | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
US7964588B2 (en) * | 2006-11-29 | 2011-06-21 | Redox Phamaceutica Co., Inc. | Method for the treatment of psoriasis |
US8741954B2 (en) * | 2007-02-21 | 2014-06-03 | Viratox, L.L.C. | Synergistic enhancement of calcium propionate |
EP2474066A1 (de) | 2009-09-03 | 2012-07-11 | E. I. du Pont de Nemours and Company | Verbesserte katalysatorbeschichtete membranen mit verbundstoff, dünne membrannen und dünne kathoden zur verwendung für direktmethanolbrennstoffzellen |
US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
US20180228749A1 (en) | 2016-06-28 | 2018-08-16 | Mehmet Nevzat Pisak | Surfactants and compositions for treatment of viral skin conditions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
US4480032A (en) * | 1980-11-13 | 1984-10-30 | Yabrov Alexander A | Natural mixture of Type I and Type II interferons |
DE3117934A1 (de) * | 1981-05-06 | 1982-12-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel |
FR2513124B1 (fr) * | 1981-07-21 | 1989-11-17 | Hayashibara Biochem Lab | Production et applications du facteur de lyse des cellules-cibles |
US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
US4481137A (en) * | 1982-02-26 | 1984-11-06 | Mochida Pharmaceutical Co., Ltd. | Glycoproteins and processes for their production |
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
IL71954A0 (en) * | 1983-06-01 | 1984-09-30 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
JPS6019719A (ja) * | 1983-07-15 | 1985-01-31 | Asahi Chem Ind Co Ltd | 抗腫瘍活性を有する蛋白質 |
EP0149551A3 (de) * | 1984-01-16 | 1987-09-23 | Genentech, Inc. | Synergistische Gamma-Interferon-Interleukin-2-Zusammensetzungen und Verfahren zur Herstellung desselben |
DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
WO1987004592A1 (en) * | 1986-02-10 | 1987-08-13 | Liposome Technology, Inc. | Controlled-release liposome delivery system |
-
1986
- 1986-02-18 US US06/830,662 patent/US4822605A/en not_active Expired - Fee Related
-
1987
- 1987-01-23 CA CA000528088A patent/CA1297006C/en not_active Expired - Fee Related
- 1987-01-30 ZA ZA87702A patent/ZA87702B/xx unknown
- 1987-02-13 AU AU68790/87A patent/AU598232B2/en not_active Ceased
- 1987-02-17 EP EP87102198A patent/EP0233629B1/de not_active Expired - Lifetime
- 1987-02-17 AT AT87102198T patent/ATE68702T1/de not_active IP Right Cessation
- 1987-02-17 DE DE8787102198T patent/DE3773953D1/de not_active Expired - Lifetime
- 1987-02-18 DK DK082287A patent/DK82287A/da not_active Application Discontinuation
- 1987-02-18 JP JP62035443A patent/JPS62240627A/ja active Pending
- 1987-04-28 IL IL82351A patent/IL82351A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK82287D0 (da) | 1987-02-18 |
US4822605A (en) | 1989-04-18 |
DK82287A (da) | 1987-08-19 |
ZA87702B (en) | 1987-09-30 |
EP0233629B1 (de) | 1991-10-23 |
AU6879087A (en) | 1987-08-20 |
JPS62240627A (ja) | 1987-10-21 |
IL82351A (en) | 1990-12-23 |
AU598232B2 (en) | 1990-06-21 |
EP0233629A1 (de) | 1987-08-26 |
ATE68702T1 (de) | 1991-11-15 |
CA1297006C (en) | 1992-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3773953D1 (de) | Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen. | |
CZ506785A3 (en) | Human tumorous necrotic factor, process of its production, dna encoding the human tumorous necrotic factor, a cell transformed by this dna, agent in which the human tumorous necrotic factor is comprised and agent suitable to treating tumors | |
MY101852A (en) | Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna. | |
ES2020011A6 (es) | Metodo de sintesis de composiciones que comprenden al menos un butano fenolico. | |
ZA854682B (en) | Synergistic mixtures of interferons and tumour necrosis factor | |
DK0668769T3 (da) | Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse | |
ATE70449T1 (de) | Zusammensetzungen von katecholischen butanen mit zink. | |
DE3278234D1 (en) | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis | |
ATE120372T1 (de) | Antikörper für die antilymphozyten- antikörpertherapie. | |
ES2151502T3 (es) | Complejos quelato y procedimientos para su obtencion. | |
EP0311616A4 (de) | Kombination von gammainterferonen und antientzündungsmitteln oder antipyretischen mitteln zur behandlung von krankheiten. | |
ES2115582T3 (es) | Preparacion y aplicaciones de interferon-gamma. | |
ES2039236T3 (es) | Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral. | |
ES2061496T3 (es) | Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante. | |
中山康子 | Miroslav NOVAK und Helma OHKENDORF-GROTEWOLD: Die japanische technishwissenschaft-liche Literatur in Deutschland | |
ES8802250A1 (es) | Un metodo para producir factor de necrosis de tumores. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |